Tome Biosciences Launches Groundbreaking Era of Genomic Medicines with $213M in Funding

Watertown, MA, December 12, 2023 (Globe Newswire) -- Tome Biosciences, Inc., the programmable genomic integration company, has initiated the introduction of a new era of genomic medicines based on programmable genomic integration (PGI). PGI facilitates the incorporation of any DNA sequence, regardless of size, into any designated genomic location. The Company has secured $213 million in Series A and B financing from investors such as Andreessen Horowitz (a16z) Bio + Health, ARCH Venture Partners, GV, Longwood Fund, Polaris Partners, Bruker Corporation, FUJIFILM Corporation, Alexandria Venture Investments, and others.

Read full article here.